Facebook Instagram Linkedin Twitter Website
Home Blog Page 53

Federal government is providing $30 million in loans to women entrepreneurs

By
IHR Magazine
-
0

 

The Government of Canada recently announced that the Women’s Enterprise Organization of Canada (WEOC) will provide loans of up to $50,000 to women entrepreneurs and business owners this fall through the Women’s Entrepreneurship Loan Fund.

The fund, which will disburse nearly $30 million in loans, is already supporting women across the country, with the majority of recipients being underrepresented women. Anker’s strength and the country’s financial security.

“Women are smart, creative, motivated and they already know how to be successful,” said the Honourable Mary Ng, Minister of International Trade, Export Promotion, Small Business and Economic Development. “What they need is opportunity, open doors and raised hands. This is exactly what our government provides through the Women’s Entrepreneurship Loan Fund. By removing systemic barriers to access to finance, we are once again leveraging the leverage to empower women entrepreneurs to reach their full potential, create local jobs and drive economic growth.”
WEOC will provide loading funds through its regional loan fund partners and is committed to working with women entrepreneurs at every stage of the application process and beyond.

“The Women’s Entrepreneurship Loan Fund empowers women entrepreneurs by providing much-needed funding and comprehensive business support that we know will ensure long-term success,” said WEOC CEO Alison Kirkland. “SMEs The backbone of Canada’s economy, now is an excellent time to devote resources to supporting the growth of women-owned businesses.”

For more information on WEOC’s Loan Fund Program, click here.

iHerb Celebrates Its 26th Anniversary of Making Health & Wellness Products Easy and Affordable

By
IHR Magazine
-
0

 

Founded in 1996 on the belief that a healthy and balanced life should be convenient and affordable for everyone, iHerb’s operation has grown into a team of over 2,400 with 11 million active customers in over 185 countries.
For over two decades, iHerb has been driven to consistently grow and innovate, based on the ethos that everybody matters. The e-commerce platform, iHerb.com, provides customers with a localized experience that makes it quick and simple for people all over the globe to shop for the finest wellness products at the very best prices.

The shop supports 16 languages, 74 currencies, and 34 localized payment options while offering over 30,000 products in categories such as Vitamins, Supplements, Sports, Personal Care, Skin Care, Beauty, Kids, Home, Grocery, and Pets. With an unparalleled international reach, shipping to over 185 countries, iHerb’s global distribution network is anchored by eight climate-controlled global fulfillment centers and inventory hubs, and a state-of-the-art distribution chain. This allows the brand to ship its products directly to consumers — never through third-party sellers — and ensure the highest quality and freshness every time.

“As we celebrate our 26th anniversary this year, we are both grateful for the journey behind us, and energized to find new, innovative ways to offer our customers the finest curated selection of quality health and wellness products at the best possible value, conveniently delivered directly to their doors,” said Emun Zabihi, CEO of iHerb. “At iHerb, we believe that everyone in the world should have easy access to products that will help them live their healthiest, best life. Our dedicated iHerb team has worked hard to provide that access for our customers everywhere possible.”

In celebration of 26 years of promoting wellness, iHerb has launched a new wellness quiz to make it even simpler for customers to find the right products to meet their health and wellness goals.

Greenspace Brands Inc. reports first quarter fiscal 2023 results

By
IHR Magazine
-
0

 

GREENSPACE BRANDS INC. REPORTS FIRST QUARTER FISCAL 2023 RESULTS, HIGHLIGHTING STABLE GROSS REVENUE AND IMPROVEMENTS IN ADJUSTED EBITDA VERSUS THE PRIOR YEAR

SUMMARY RESULTS OF QUARTER ONE FISCAL 2023:
Gross Revenue from continuing operations was $5.1 million, representing a 26.6% improvement versus the prior quarter ended March 31 20221 and in line with the prior year 2. Gross Revenue compared to prior year reflects the following counter-balancing factors: (i) during the fiscal year ended March 31, 2021 certain customers decided to reduce or stop doing business with the Company due to poor customer service levels, but were still doing some business with the Company last year, positively impacting the three-month period ended June 30, 2021; (ii) a one-time inventory pipeline replenishment by certain customers positively impacted the comparative period ended June 30, 2021; (iii) price increases implemented in response to increasing costs during the prior twelve months positively impacted the period ended June 30, 2022; (iv) several new product listings from the Company’s largest customer positively impacted the current period; and, (v) the portfolio simplification implemented as part of the Project FIT initiative reduced active stock keeping units (“SKUs”) across the business that enabled the Company to achieve higher gross revenue per SKU, on this simplified portfolio.Gross Profit Percentage was 20.4% of net revenue compared to 22.6% in the prior year 2, largely attributable to: (i) inflationary pressures leading to higher input costs; (ii) the return to higher promotional activities to drive growth of the branded business; (iii) listing fees incurred for broadening the distribution of existing and margin-accretive new products in the portfolio, which were not incurred during the same three-month period of the prior year; partially offset by, (iv) the positive impact of pricing actions implemented in the prior fiscal year; and, (v) a decrease in the provision for obsolete inventory compared to the same three-month period of the prior year. Excluding listing fees incurred during the three-month period ended June 30, 2022, the Company’s adjusted gross profit percentage was 22.0%, generally in-line with the prior year period. It is important to note that the Company has announced additional price increases to its customers during the quarter to help offset industry-wide inflationary pressures. These additional price increases are expected to protect gross profit percentage over subsequent periods. In addition, the Company continues to progress its Project FIT cost savings initiatives which are expected to help achieve its gross profit percentage targets.

Selling, General and Administrative (“SG&A”) expenses of $1.6 million improved by 15.8% compared to $1.9 million in the prior year2 with significant reductions in salaries and benefits. This improvement reflects the Company’s progress in reducing SG&A expenses as it executes its Project FIT initiatives.

Net Loss of $1.8 million, compared with a $0.3 million net loss in the prior year 2, was primarily attributable to: (i) restructuring gains of $1.2 million recognized in the prior year; (ii) higher accretion expense recorded during the period of $0.5 million (2021 – $0.1 million); (iii) lower salaries and benefits expenses of $0.7 million for the current period (2021 – $1.1 million); (iv) higher rebates and discounts of $0.9 million for the current period (2021 – $0.7 million); and, (v) foreign exchange gains of $0.1 million for the current period (2021 – $0.1 million loss).

Adjusted EBITDA3 of negative $0.6 million was improved 24.1% compared to the prior year2, reflecting the matters described above.

1-Quarter 1 Fiscal 2023 compared to Quarter 4 Fiscal 2022.
2-Quarter 1 Fiscal 2023 compared to Quarter 1 Fiscal 2022.
3-See “Non-IFRS Financial Measures And Key Metrics” below. EBITDA adds back certain non-cash items to net income or loss from continuing operations and is used by Management to measure operating performance.  Adjusted EBITDA further adjusts EBITDA by adding back income or expenses of a non-cash, non-recurring, unusual or one-time nature.  Refer to the Company’s Management Discussion and Analysis”This past year we have been implementing our Focused Growth Strategy across the business and heightening our drive towards profitable growth,” said Shawn Warren, President and CEO of GreenSpace Brands Inc. “We are seeing encouraging progress with broader retailer support, new distribution wins with large retailers and continued Project FIT cost savings initiatives.  To address inflationary pressures across our industry, we have announced a series of additional pricing actions for retail and foodservice customers.  Overall, Management is optimistic that Fiscal 2023 will show continued adjusted EBITDA improvements with better topline growth and improved gross profit percentages as we continue to focus and simplify the business.”

OUTLOOK:
Management believes that its new Vision, Strategic Plan and implementation of its Focused Growth Strategy will lead to improvements in adjusted EBITDA that will continue into subsequent years.  The Company has improved customer service levels across all three of its branded businesses, leading to the resumption of widespread promotional activities with select retailers. The Company has been able to regain distribution with certain strategic customers and has been able to make inroads into launching margin-accretive new products and new channel growth across e-commerce platforms.  Aligned with its Focused Growth Strategy, Management has prioritized improvements in gross profit percentage and overall profitability through better product mix, price increases and enhanced cost management at all levels.

GreenSpace has been able to rebuild credibility with its supplier base and renegotiate payment terms with a number of key suppliers across its ingredient and manufacturing network.  While rebuilding customer revenue momentum may take time after the working capital challenges of the previous two years, Management expects that the foundational elements have been established to deliver improvements in both topline performance and profitability.  Management believes that its Focused Growth Strategy will continue to drive improvements in the operation over time and remains optimistic that this initiative will improve adjusted EBITDA to help finance the future growth opportunities available to the Company.

CORPORATE UPDATE:
On June 2, 2022, the Company announced that it had initiated a review of strategic alternatives to enhance shareholder value, which would consider a range of potential strategic alternatives.  The Company engaged financial advisors to assist in the review and no formalized timetable was established for the completion of the strategic review.

Almost all of the Company’s loans payable mature on or around September 30, 2022 and extension, renewal or replacement facilities have not yet been arranged.  There can be no certainty that Management will be successful in its negotiations with the current or alternative lenders to extend or replace these facilities nor is there certainly that the terms of any extension or replacement facility will be as favourable as the existing terms.

Good natured Products Inc. Announces Quarterly Financial Results

By
IHR Magazine
-
0

 

Good natured Products Inc. Announces Quarterly Financial Results for the Three and Six Months Ended June 30, 2022.

For Q2 2022, the Company delivered another quarter of positive adjusted EBITDA1 coupled with strong growth in revenues. Gross margins remained in the targeted range despite continued inflationary pressure, while growth in revenue and gross profit outpaced increases in operating expenses.
Revenue in Q2 2022 grew on a year-over-year basis by 106% to $25.5 million, driven by strong organic growth, increases in average selling price per unit and contribution from strategic acquisitions. The Company’s active business-to-business (“B2B”) customer accounts grew to over 1,400 as at June 30, 2022.

“I remain incredibly proud of our team’s unwavering commitment to serving our customers while navigating challenging market conditions and inflationary pressures over the last few quarters. We’ve delivered another solid quarter of growth by focusing on strong execution and leveraging our investments in production capability, like with our recent acquisition of FormTex Plastics in Houston,” stated Paul Antoniadis, CEO of good natured®. “In future quarters, you’ll continue to see our commitment to strong execution and productivity improvements that are laying the foundation to profitably scale our business and the associated positive environmental impact that comes with our growth.”

Key Highlights

Revenues for Q2 2022 increased 106% to $25.5 million compared to $12.4 million for the three months ended June 30, 2021 (“Q2 2021”). H1 2022 revenues increased 154% to $51.5 million compared to $20.3 million for the six-month period ended June 30, 2021 (“H1 2021”).

Variable gross profit1 for Q2 2022 increased 97% to $8.5 million, representing a variable gross margin1 of 33.1%, compared to $4.3 million and 34.7% for Q2 2021. Variable gross profit for H1 2022 increased 122% to $16.7 million, 32.4% of sales, compared to $7.5 million, 37.1% of sales, in H1 2021.

Gross profit for Q2 2022 increased 92% to $6.7 million representing a gross margin of 26.4%, compared to $3.5 million and 28.3% respectively for Q2 2021. Gross profit for H1 2022 increased 113% to $13.4 million, 26.0% of sales, compared to $6.3 million, 31.1% of sales, in H1 2021.

Selling, general and administrative (“SG&A”) expenses, excluding acquisition activity and one-time charges,1 for Q2 2022 and H1 2022 were $4.0 million and $7.5 million compared to $2.2 million and $3.8 million for Q2 2021 and H1 2021. As a percent of sales, SG&A expenses, excluding acquisition activity and one-time charges,1 declined to 16% for Q2 2022 and 15% for H1 2022 compared to 18% in Q2 2021 and 19% in H1 2021.

SG&A expenses for Q2 2022 and H1 2022, including acquisition activity and one-time charges, were $4.6 million and $8.4 million compared to $3.2 million and $4.9 million for Q2 2021 and H1 2021. As a percent of sales, SG&A expenses declined to 18% for Q2 2022 and 16% for H1 2022 compared to 26% in Q2 2021 and 24% in H1 2021.

The Company’s adjusted EBITDA1 for Q2 2022 and H1 2022 was $1.0 million and $2.2 million respectively, compared to a loss of $0.2 million for Q2 2021 and break-even for H1 2021.

In Q2 2022, the Company incurred a net loss of $3.0 million compared to a net loss of $3.7 million in Q2 2021. Net loss for H1 2022 was $4.6 million compared to a net loss of $5.6 million in H1 2021.

Subsequent to quarter end, on August 26, 2022, the Company announced that it had completed a senior secured revolving credit facility with Wells Fargo Bank, N.A., through its wholly owned subsidiary Well Fargo Capital Finance Corporation Canada, of up to USD $55 million and closed a $6.6 million mortgage financing with Business Development Bank of Canada. Further details regarding these announcements can be found in the Company’s press release dated August 26, 2022.

Ghana: 50 medical journalists are being trained to promote naturopathy

By
IHR Magazine
-
0

 

The Faculty of Holistic Medicine and Technology at Nyarkotey University has trained 50 medical journalism students in naturopathic medicine to advance the practice and profession of naturopathic medicine in Ghana. The Faculty has achieved great recognition in the field of modern naturopathic medicine under the guidance of Professor Raphael Nyarkotey Obu, Professor of Naturopathic Health Sciences and renowned medical and scientific writer for national newspapers.

According to Professor Raphael Nyarkotey Obu, medical and scientific writings have brought him great recognition, especially in areas that are overlooked by many. Therefore, he found it necessary to train naturopathic medicine students in medical and scientific reporting to help them write articles on scientific topics. The presenters of the program come from medical and journalism backgrounds.

Ruth Narkie Nartey received top honours in medical journalism as a naturopathic student.

Noting that medical journalism appears to be new to Ghanaian jurisprudence, Professor Nyarkotey believes that the education and successful completion of naturopathic medical students is important to the public because of misinformation and reporting, especially regarding the practice of herbal, complementary and alternative medicine Because of the lack of knowledge in the mainstream, this is an important area that I would like you to spread as journalists, he said.

Professor Nyarkotey, whose articles most often make headlines in national newspapers, also noted: “It is unfortunate that in Ghana we have managed to downgrade our local food and natural remedies while other countries make millions. But I’m glad there’s a new revolution in the media that supports the articles I publish regularly.”

He also noted that his frequent posts have sparked a big national debate about whether our local food is good. “Through my articles, many people have discovered that not all starchy foods are bad for our health because the news of starchy foods has become a bad public image. Today, we know from science that we learn from local delicacies Resistant starches, such as tapioca fufu, Gary, etc., obtained in gluten, are good for our gut health because they resist digestion.”

He is quick to add: “While medical news articles are often effective at conveying public health information, they often convey false or misleading information about health care, partly because journalists do not know or cannot communicate the results of clinical trials, and partly because They don’t know.”. This can lead to unrealistic expectations due to the aggressive medical procedures and experimental techniques involved. “

Prof Nyarkotey added that the mass media can also trigger a “communication storm” to draw attention to a single health problem, which has been portrayed for years as a disparagement of herbal and alternative remedies. “Your role in medical journalism also affects the quality of a person’s healthcare. So I urge everyone to be studious and to strive for excellence. Don’t be led by money and short-term success. But be bold, brave, and confident. In Medical News build a good brand in the world, and I can tell you where that takes you.” He called on naturopaths to become the new wine of medical journalism to advance the naturopathic profession.

Life Time President and CFO, Tom Bergmann, to Retire from Company

By
IHR Magazine
-
0

 

Life Time President and CFO, Tom Bergmann, to Retire from Company on December 31, 2022; Company Also Named Robert Houghton Executive Vice President and CFO Effective August 28, 2022; Bergmann to Remain President and Assist with Transition through End of Year.

Life Time® Group Holdings, Inc. (“Life Time,” “we,” “our,” or the “Company”) (NYSE: LTH) today announced that President and Chief Financial Officer, Thomas (Tom) Bergmann, has decided to retire from the Company on December 31, 2022. In conjunction with Bergmann’s retirement, the Company also announced that Robert (Bob) Houghton has been named Executive Vice President and Chief Financial Officer effective August 28, 2022. Bergmann relinquished his Chief Financial Officer role concurrent with Houghton’s election and will remain President to support the transition through the end of 2022.

Bergmann joined Life Time in February 2016 as President and Chief Financial Officer. His operational and financial leadership has played a central role in the Company’s continued expansion and growth, positioning Life Time well for the future. In addition to building a strong finance team, he also led significant equity and debt transactions for the Company, including minority equity investments, multiple debt capital market transactions and the October 2021 initial public offering.

Houghton brings to Life Time broad experience in finance, extensive financial planning and analysis (FP&A) skills and senior leadership experience, having served as Senior Vice President – Finance at United Natural Foods, Inc. (UNFI), a North American distributor of natural and conventional grocery and non-food products, since May 2020. While at UNFI, Houghton led the strategy, development and execution of enterprise-wide FP&A, investor relations, financial systems, finance integration and business continuity programs. Prior to that, he served as Vice President – Corporate Finance and Treasurer and Vice President – Investor Relations for C.H. Robinson, a global third-party logistics company, from 2018 to April 2020. Houghton also held finance leadership roles with Sherwin-Williams, Valspar, General Mills and International Paper Company between 1993 and 2018.

Commenting on Bergmann’s retirement from Life Time and Houghton joining the Company, Life Time Founder, Chairman and Chief Executive Officer, Bahram Akradi, said, “I want to thank Tom for his tremendous leadership and contributions as a member of our executive leadership team. I’m very grateful for his partnership, particularly as we returned to the public market last year and navigated our way through the significant impact of the pandemic. I’m also pleased to welcome Bob to our executive leadership team. With his proven track record in financial leadership and FP&A expertise, I look forward to the impact he will have in guiding our finance functions as we continue to build our highly coveted healthy way of life company and brand with an unwavering commitment to serving members and shareholders.”

Intolerant Uses Digestive Enzymes to Manage Starch and Sucrose Intolerance

By
IHR Magazine
-
0

 

Intoleran has a reputation as a company that enables people to enjoy food again. This comes from the Dutch health brand’s range of digestive enzyme products, which help its customers manage food intolerances.

Unlike a food allergy — which is a reaction of the body’s immune system — food intolerances are a purely digestional affair. They occur when the body cannot create enough of a particular digestive enzyme to break down the food that an individual consumes. In the case of starch and sucrose intolerance, the body doesn’t create enough of the enzyme sucrase-isomaltase. This typically comes from a condition known as congenital sucrase-isomaltase deficiency (CSID).

There are multiple ways to address a lack of enzymes to break down starch and sucrose. The first recommendation by dieticians — including those at Intoleran — is to adjust an individual’s diet. However, both sucrose and starch are prevalent in modern foods, which can make an effective diet challenging.

“If you suffer from an intolerance, you need to adjust your diet first,” says Intoleran owner Harmen Treep, “However, there are many occasions where you don’t know what you’re eating. That’s when starchway can be a lifesaver.”

Intoleran’s starchway supplement was uniquely designed to address starch and sucrose digestional deficiencies. The product contains the enzymes Glucoamylase and Invertase and has been specially formulated to help the body break down stubborn starches and sucrose.

As with all of Intoleran’s supplements, starchway is clean, uses minimal ingredients, avoids unnecessary additives, and is vegan. It’s a high-quality supplement designed to help individuals manage pesky intolerances and restore an ability to truly enjoy their food again — even when they don’t have control over every detail of what they’re eating.

Good Good brand, the fastest growing jam brand in the U.S.A., launches an innovative all-natural peanut butter spread

By
IHR Magazine
-
0

 

Our Peanut Butter products – PBCrunchy and PBCreamy are now available in the US. Coming soon to Canada, UK, Europe and through distribution.

Real peanut butter contains 90% or more peanuts. That’s why most companies that call out keto-friendly and low-carb can’t call themselves real peanut butter. Our goal with this innovation was to deliver a modern-day peanut butter classic. It is made for the true peanut butter lovers out there.

Containing healthy fats – 83% (17g/serving) of the fat comes from polyunsaturated and monounsaturated fats. We added dietary fibres made from halal chicory root, which also adds a hint of natural sweetness. Our peanut butter is 99% sugar-free and free from added sugar. Sourcing our peanuts from North America (U.S.A specifically) enables a lower carb count. By roasting the peanuts during processing, we boost the antioxidant effect of Coumaric Acid up to 22% (Craft et al., 2010).

A mouth-watering, rich and decadent nut butter that preserves all the things we love about peanut butter.

New Report Reveals Behavioral Factors to Treatment Adherence

By
IHR Magazine
-
0

 

Fullscript released a report about behavioural change in integrative medicine as part of its mission to change how health is prescribed and help people get better. The findings indicated that while behaviour or lifestyle change is challenging, there are clear benefits to adopting new health behaviours and evidence-based strategies that practitioners can use to support their patients.
The comprehensive report, which was produced internally by a team of Fullscript medical researchers, writers, and health professionals, and peer-reviewed by the Institute for Natural Medicine, included a literature review and a large patient survey.
The purpose was to support integrative practitioners in making treatment recommendations by identifying barriers and strategies that influence change and helping patients adhere to health-promoting behaviours.

“Integrative medicine is well poised to address these challenges through regular engagement, by increasing motivation, and by incorporating lifestyle-based support,” said Dr. Christopher Knee, ND, MSc, medical education and research manager, the integrative medical advisory team at Fullscript. “Those lifestyle-based behaviours include nutrition, exercise, mindfulness, and sleep.”

The study revealed that 93 percent of the 605 patients surveyed felt that at least some change was needed to improve their health, and as they continued to work with their practitioners, they became more ready to change. In addition, patients felt most successful with changing their supplement intake and dietary or nutrition behaviours but reported that lifestyle treatments such as stress management, physical activity, or improving sleep habits were harder to follow.

The most common barriers to adherence and behavioural change for patients working with integrative practitioners were cost, time, and motivation.

“Practitioners can use techniques such as motivational interviewing, and other measurement tools such as patient questionnaires, to determine which barriers are most impactful to a patient or the areas where they may need extra support,” Knee added. “The goal is to identify whether patients are ready to change, and what type of support they need to feel empowered.”

Strategies such as providing education and simplifying treatment plans; receiving monitoring and feedback from practitioners; and setting up goals, plans, and commitments, were all impactful. Additionally, the use of evidence-based technologies was found to be a cost-effective means for practitioners to deliver successful behavioural change support.

The ultimate goal of the study was to better equip practitioners to support long-term change and improve health outcomes for their patients.

You can view and download the entire behavioural change report here. To learn more about Fullscript, go to Fullscript.com.

Study: Pycnogenol® Helps Relieve and May Prevent Symptoms of Restless Legs Syndrome

By
IHR Magazine
-
0

 

“Restless Legs Syndrome is often missed or dismissed in diagnosis, but it’s a real health condition often rooted in microcirculation. Many patients feel helpless and unheard because the symptoms seem to be exaggerated or imagined. It’s not in your head – it’s in your legs, and this research shows there are steps you can take with a powerful natural ingredient that may help you feel better,” says author and renowned natural physician, Dr. Fred Pescatore.
New scientific findings offer hope and a natural solution to those who suffer from sensations of crawling, pulling, throbbing, aching and itching in the legs, often resulting in sleep disruption and the uncontrollable urge to move. Restless Legs Syndrome (RLS) impacts nearly 10 percent of the U.S. population and can lead to other health concerns. A new study found Pycnogenol® French maritime pine bark extract, a leading natural anti-inflammatory and circulation booster, to significantly relieve and prevent symptoms associated with Restless Legs Syndrome.
Frustrating symptoms can begin at any age and worsen. Most who suffer from this condition feel sensations of crawling, pulling and throbbing after long periods of sitting or lying down, such as sleeping or sitting at a desk. Moving the legs typically temporarily relieves the discomfort, but the sensations can reoccur after movement stops. Those who have Restless Legs Syndrome can also suffer from poor sleep quality, fatigue and higher stress levels, which can impact other aspects of daily life.

The study, published in Panminerva Medica, tested 45 subjects with Restless Legs Syndrome. Twenty-one (21) subjects were supplemented with 150 mg of Pycnogenol® per day, while another 24 subjects followed a standard management routine in the control group. After four weeks, subjects in the Pycnogenol® group showed significant improvement in all prominent symptoms of Restless Legs Syndrome, including:

33 percent decrease in crawling (vs. 3 percent decrease in control group)
30 percent decrease in creeping (vs. 7 percent decrease in control group)
41 percent decrease in pulling (vs. 7 percent decrease in control group)
63 percent decrease in throbbing (vs. 6 percent decrease in control group)
72 percent decrease in aching (vs. 3 percent decrease in control group)
48 percent decrease in itching (vs. 10 percent decrease in control group)
52 percent decrease in electric shocks (vs. 17 percent decrease in control group)
61 percent decrease in sleep problems (vs. 16 percent decrease in control group)
Research indicates that as many as 22 percent of those with Restless Legs Syndrome also have venous insufficiency. While additional research is needed to determine the relationship between Restless Legs Syndrome and edema, this study found that 81 percent of subjects in the Pycnogenol® group improved their status of minimal edema.

Additionally, after four weeks, the need for pain management was significantly reduced for those in the Pycnogenol® group.

“Even when Restless Legs Syndrome is properly diagnosed, medication to treat the condition includes pharmaceuticals that increase dopamine in the brain, resulting in side effects like nausea and sleepiness. Opioids or narcotic medications may be used to relieve more severe symptoms and can be extremely addictive,” says Dr. Pescatore.

“Pycnogenol® is an all-natural solution. Decades of research and global market availability show this circulation booster is safe and effective and is especially recognized as an ingredient at the forefront of naturally improving blood circulation. This study now shows its effects specifically on symptoms related to Restless Legs Syndrome,” said Dr. Pescatore.

1...525354...389Page 53 of 389

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

© 2026 IHR Magazine | Canada's Natural Health Industry Authority | Le guide de l’industrie canadienne de la santé naturelle